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Summary
There has been a lot of progress in mushroom science and biotechnology in the last
decade. The optimization of PFGE separation of fungal chromosomes allowed the study of
the molecular karyotype of mushrooms and the assignment of genes to chromosomes.
There are 115 genes encoded from different species of mushrooms. Cross breeding contin-
ues to be the principal method, but it is accompanied by the analyses of RAPD or RFLPs
methods. The genetic makers are used and introduced into commercial large hybrids via
introgression breeding. The complex traits such as yield, resistance to disease and quality
characteristics, and quantitative traits more than one quantitative trait locus (QTL) are
found and used in practice. The transformants or transgenic mutant strains were obtained
by Agrobacterium system or particle bombardment. At least 651 species representing 182
genera of hetero- and homobasidiomycetes mushrooms were researched containing anti-
tumor or immunostimulating polysaccharides. Ergosterol in the lipid fraction was identi-
fied as one of the most active constituents. New sesquiterpenoid hydroquinones, steroids,
oxalic acid, triterpenes, water-soluble lignins, sulfated polysaccharides, protein-bound poly-
saccharides are researched intensively as antimicrobial or antiviral agents. Many small mo-
lecular mass compounds exhibit cytotoxic activities, such as illudins, leaianafulvene, triter-
penes (ganoderic acids), acetoxyscirpenediol, ergosterol peroxide, sterols. There are many
other compounds or activities found in the mushrooms, such as antioxidative, hypoglyce-
mic action, anti-inflammatory effect, hepatoprotective compounds, psychoactive compounds
and activities.
Key words: cytogenetics, genetic breeding, antimicrobial, antitumor, mushrooms, dietary
supplement
Introduction
For millennia, mushrooms have been valued as ed-
ible and medical provisions for humankind. With the
popularization of mushroom farming and/or industrial-
ization, mushroom production worldwide continues to
increase. It is estimated that more than 10 million metric
tonnes of edible and medicinal mushrooms were pro-
duced last year in various countries (1). Mushroom
production can convert the huge lignocellulosic waste
materials into a wide diversity of products (edible or
medicinal food, feed and fertilizers), protecting and re-
generating the environment. In addition, the mushroom
production can generate equitable economic growth that
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has already had an impact at national and regional lev-
els. This impact is expected to continue increasing and
expanding in the future, because more than 70 % of ag-
ricultural and forest materials are nonproductive and
have been wasted in the processing. The mushroom con-
version has been named the »non-green revolution« (2,3).
However, the mushroom science is a relatively new ap-
plied science and the mushroom industry is still small
compared to many plant crops, so the investment is limi-
ted. As a consequence, scientific research on mushrooms
generally lags behind that of plant and animal (4). This
article deals with the advances of mushroom science and
biotechnology in the last decade.
Genetics and Breeding of Mushrooms
Cytogenetic study
The molecular karyotype of mushrooms has not
been fully clarified yet because of small size of the chro-
mosomes and the occurrence of endomitosis (5). Differ-
ent chromosome numbers and genome sizes have been
reported by using various analytical techniques, includ-
ing microscopy, restriction fragment length polymor-
phism (RFLP) analysis, and PFGE. However, the results
are sometimes contradictory, for example, the number of
chromosomes in Pleurotus ostreatus ranges from 6 to 10
(5–7). In the last decade, the optimization of PFGE sepa-
ration of fungal chromosomes (7) allowed the study of
molecular karyotype of mushrooms and the assignment
of genes to chromosomes. The genome of Agaricus bispo-
rus consists of 13 chromosomes, and its total size is 31
Mbp (8). Pleurotus ostreatus contains 11 pairs of chromo-
somes with sizes ranging from 1.4 to 4.7 Mbp (9). There
is no report for other mushrooms in this respect.
Encoded genes of the principal mushrooms
Gene cloning is one of the most active areas in mush-
room science. Along with the PCR-based techniques and
equipments popularized in the laboratory, the genes have
been cloned rapidly and encoded with complete cds,
other than partial cds before. According to the National
Center of Biotechnology Information (NCBI), the encod-
ed genes of the principal mushroom species (edible and
medicinal mushrooms) were included in this respect.
Here are counted just the genes with complete cds, ex-
cluding the genes with partial cds (or regions), ribo-
somal RNA genes, mitochondrial complete genome or
genes for mitochondrial product, ITSs. The largest group
is from Coprinus cinereus, which includes 115 encoded
genes, such as laccase precursor genes, mating-type pro-
tein b1 (b1) genes and alleles, pheromone receptor and
precursor genes. There are 87 genes encoded in Schizo-
phyllum, 46 in Pleurotus, including P. ostreatus, P. sajor-
-caju, P. cornucopiae, P. eryngii and P. djamor. There are 25
genes encoded in Agrocybe and in Lentinula, 23 genes en-
coded in Agaricus bisporus, 12 genes in Genoderma, 7 in
Flammulina, 6 in Polyporus and Pholiota, 3 in Hericium and
Grifora. There are 2 genes encoded in Volvariella volcacea,
and 1 in Auricularia polytricha. The genes detailed can be
checked in the GenBank (10).
Breeding strategies
High production and good quality are always the
principal goals for agriculturally important crops, with-
out the exception of mushrooms. There are a lot of
breeding methods, such as mass selection based on the
natural chance mutation and programmed mutation, in-
cluding ionizing radiation (X-rays, neutrons, g-rays, la-
ser beams, ultraviolet light) and chemicals, cross breed-
ing and transgenic breeding. However, the cross and
transgenic breeding are more objective and promising,
and have made a lot of progress from the theory to the
practice in the last decade.
Cross breeding
Since the first cross breeding, which happened in
1983, generating two Agaricus bisporus hybrids Horst U1
and Horst U3 (11), a lot of hybrids have been created,
including Lentinula edodes (12,13), Pleurotus and other
mushroom species (12). The breeding of strains has tra-
ditionally been accomplished by trial and error, and large
numbers of hybrids, obtained by pairing monosporic
cultures, need to be cultivated to evaluate the produc-
tion characteristics, accompanied by analyses of RAPD
or RFLPs methods (14–16).
However, there has been an enormous increase dur-
ing the last decade in the efficiency of generating DNA
markers by PCR based techniques. Repetitive DNA se-
quences are in this respect very useful because a num-
ber of markers can be generated in each individual PCR
reaction. Advanced computer software is available that
can use the experimental data to generate genetic maps.
Thus comes the era of the genetic maps that guide the
cross breeding objectively and accurately (17–19).
The use of genetic makers is straightforward for mo-
nogenic traits that segregate in distinct phenotypes such
as cap colour in mushrooms (20,21). Previously, genetic
analyses have shown that the cap colour of Agaricus bi-
sporus is mainly determined by one single locus on chro-
mosome 8 and that the brown allele is dominant (22,23).
An isoenzyme marker linked to the trait was found and
the molecular markers based on repetitive elements that
are very tightly linked to the cap colour were generated.
These markers have been used to introduce the brown
cap colour of a wild line into a commercial large hybrid
via introgression breeding (22). Another example is the
introduction of sporeless trait to the commercial strain
of Pleurotus ostreatus, because most people that handle
and harvest this crop develop respiratory disease (4,21,
22).
However, complex traits such as yield, resistance to
disease and quality characteristics are usually inherited
quantitatively. For quantitative traits, more than one
quantitative trait locus (QTL) is normally found. Larraya
et al. (24) found 1 to 4 QTL for each of several diverse
agronomic traits in the oyster mushroom P. ostreatus. Mo-
quet et al. (25) found only one QTL for sensitivity to bac-
terial blotch caused by Pseudomonas tolaasii in A. bispo-
rus. Sonnenberg et al. (4) found two significant QTL in
one homokaryon of the wild line and five QTL in the
other wild homokaryon of A. bisporus resistant to Verti-
cillium fungicola. After some intercross single spore iso-
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lates (SSIs) of the backcross, some hybrids proved to be
less sensitive to infection.
Transgenic breeding
The advent of a tractable method for DNA transfer
in mushroom has created new vistas for the genetic en-
hancement. The first transformant was of Agaricus bispo-
rus by the end of 1993 (26–28). The recipient strain used
initially was the adenin-auxotrophic strain (ATCC 24663),
which appeared to form protoplasts very efficiently and
responded well to the selection with hygromycin. Later
on, the protocol also appeared applicable to a derivative
of commercial strain Horst U1 (ATCC 62462). Fertile
crosses between the transgenic mutant strain and a U1
homokaryon were easily obtainable. After filing a PCT
patent (28) and the first communication at the Vancou-
ver Congress in 1994 (29), this work was published as
well as the results on highly efficient homologous, site-
-directed integration of the transformation plasmid that
contained the A. bisporus b-1,3-glucanase gene (30,31). The
first target was to study mushroom browning, for which
A. bisporus tyrosinase genes were isolated and one of
them was introduced in the antisense orientation. Either
approach using site-directed integration or antisense in-
hibition was supposed to provide straightforward tools
for gene silencing in A. bisporus. However, the multinu-
clear nature of fertile A. bisporus mycelia presented an
additional problem (32,33). Another challenge was to
isolate and identify the A. bisporus mannitol dehydroge-
nase (MtDH) gene. With mannitol being the most abun-
dant metabolite (up to about 50 % dry mass and exclud-
ing water), white button mushrooms might as well be
considered mannitol-rooms. In collaboration with a Swiss
group (J. Sassoon and U. Baumann, University of Bern),
the MtDH 3-dimensional structure has become available
(34,35), which would now allow, in principle, the gener-
ation of transgenic mushrooms containing altered man-
nitol profiles or altered MtDH enzymes and, thus, would
allow the study of the function(s) of mannitol. Ultima-
tely, such activities might also yield new commercial
strains with, for example, a higher dry matter content or
better pathogen resistance.
Other transformation protocols
More recently, a novel transformation protocol for
different fungal species, including commercial heteroka-
ryotic A. bisporus strain Horst U1, has been described
(27,35), which is based on infection with the plant-pa-
thogenic bacterium Agrobacterium tumefaciens and induc-
tion of its virulence (vir) gene with the plant hormone
acetosyringone. Chen et al. (36) have modified Agrobac-
terium-mediated method for the efficient transformation
of Agaricus bisporus. Salient features of this procedure in-
clude cocultivation of Agrobacterium and fruiting body gill
tissue and use of a vector with a homologous promoter.
This method offers new prospects for the genetic manip-
ulation of mushroom species. The Agrobacterium system
allows the transformation of both homokaryons and he-
terokaryons of A. bisporus. Also, both karyotypes of a
heterokaryon can be transformed simultaneously. Further-
more, the first report on the transformation of vegetative
mycelium of a commercial strain of A. bisporus appeared
(37).
An alternative way to introduce donor DNA into a
vast number of organisms, including many plant and
fungal species, and even intact tissues, is particle bom-
bardment (38). This technique is based on gas-driven
bombardment with tungsten or gold particles coated with
the donor DNA, thus penetrating the recipient tissue. A
number of reports describe its use for transformation of
intact plants and for a number of fungi (38). Guo et al.
(39) reported that the thermal hysteresis protein gene
was integrated into Volvariella volvacea genome through
particle bombardment. The transformants showed stron-
ger cold tolerance than the host strain.
Active Compounds of Mushrooms
Antitumor polysaccharides or peptideglycan
Polysaccharides or peptideglycan, pharmaceutically
active mushroom compounds, continue to be the subject
of most researches, including isolation, chemical struc-
tures and experiments in vitro or in vivo. Ten years ago
the researches were concentrated on the four mushrooms,
Lentinus (Lentinula) edodes, Schizophyllum commune, Gri-
fola frondosa, and Sclerotinia sclerotiorum, particularly their
respective b-glucans, lentinan, schizophyllan (also called
SPG, sonifilan, or sizofiran), grifolan, and SSG. Most of
them, b-(1-6)-branched b-(1-3)-linked glucans, were found
to exhibit significant antitumor activity (40). In recent
years, little additional research has been conducted with
these four mushrooms, but a host of other species has
been investigated and a variety of species has been ex-
plored (41,42). At least 651 species representing 182 gen-
era of hetero- and homobasidiomycetes mushrooms con-
tain antitumor or immunostimulating polysaccharides
(43–46).
There are also several reports of mushrooms con-
taining more than one polysaccharide with antitumor
activity (47). An interesting example is A. blazei. It con-
tains an antitumor glucan with a b-1,6 backbone (48–50),
which differs from the b-1,3 backbone with b-1,6 bran-
ches shared by many other antitumor glucans. In addi-
tion, a glucomannan with the main chain of b-1,2-linked
D-mannopyranosyl residues has been isolated from this
mushroom and found to inhibit tumorigenesis (50).
There is evidence that b-D-glucans induce a biologi-
cal response by binding to membrane complement re-
ceptor type 3 (CR3, alpha Mb2 integrin or CD11b/CD18)
on immune effector cells. The ligand–receptor complex
can be internalized. The intercellular events that occur
after glucan-receptor binding have not been fully deter-
mined until now (51). In a recent experimental approach
it has been shown that schizophyllan produced by S.
commune is able to bind the mRNA poly(A) tail (52).
Molecular mass, degree of branching, number of substi-
tuents, as well as ultrastructure, including the presence
of single and triple helices, significantly affect the bio-
logical activities of b-glucans (53–55). Higher antitumor
activity seems to be correlated with higher molecular
mass, lower level of branching and greater water solu-
bility of b-glucans (40). However, the high branched
MD-fraction from G. frondosa (Mr = 1 000 000–1 200 000
Da) exerts a high antitumor activity (56).
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Other antitumor compounds
The lipid fraction of A. blazei was found to contain a
compound with antitumor activity, subsequently identi-
fied as ergosterol (57). The lipid fraction of Grifola fron-
dosa exhibited antioxidant activity and inhibited the cy-
clooxygenase enzymes, COX-1 and COX-2 (56,58). Ergo-
sterol was again identified as one of the most active con-
stituents. Oxidative damage is strongly implicated in the
development of many chronic diseases, including can-
cer. The inducible form of COX, COX-2, also appears to
play an important role in certain cancers. Its inhibition
can result in the inhibition of tumor development, and it
appears to be beneficial even in some established tu-
mors (59). Other mushroom constituents may inhibit pro-
motion or progression by exerting direct cytotoxicity
against tumor cells (60), interfering with tumor angio-
genesis, or upregulating other nonimmune tumor-sup-
pressive mechanisms.
Antibacterial compounds
New sesquiterpenoid hydroquinones, produced by
the European Ganoderma species Ganoderma pfeifferi Bres.
and named ganomycins, inhibit the growth of methicil-
lin-resistant Staphylococcus aureus and other bacteria (61).
Besides, whole extracts of this mushroom inhibit the
growth of microorganisms responsible for skin problems
(Pityrosporum ovale, Staphylococcus epidermidis, Propionibac-
terium acnes, unpublished results). Steroids like 5a-ergo-
sta-7,22-dien-3b-ol (3) or 5,8-epidioxy-5a,8a-ergosta-6,22-
-dien-3b-ol (62,63), isolated from Ganoderma applanatum
(Pers.) Pat., proved to be weakly active against a num-
ber of Gram-positive and Gram-negative microorganisms
(63). Oxalic acid is an agent responsible for the antimi-
crobial effect of Lentinula edodes (Berk.) Pegler against S.
aureus and other bacteria (64). Ethanolic mycelial ex-
tracts from L. edodes possess antiprotozoal activity against
Paramecium caudatum (64). The antimicrobial activity of
Podaxis pistillaris (L.: Pers.) Morse, used in some parts of
Yemen for the treatment of nappy rash of babies and in
South Africa against sun burn (65), is caused by epico-
razins. These substances belong to the group of epipoly-
thiopiperazine-2,5-diones, an important class of biologi-
cally active fungal metabolites (65). Other antimicrobial
compounds from the Aphyllophorales were summarized
by Zjawiony (54).
Antiviral compounds
Several triterpenes from Ganoderma lucidum (M.A.
Curtis: Fr.) P. Karst. (i.e. ganoderiol F, ganodermanon-
triol, and ganoderic acid B) are active as antiviral agents
against human immunodeficiency virus type 1 (HIV-1).
Ganoderic acid B inhibits HIV-1 protease with an IC 50
value of 0.17 mM (66,67). Ganodermadiol, lucidadiol
and applanoxidic acid G, isolated from G. pfeifferi, but
also known from other Ganoderma species, possess in vi-
tro antiviral activity against influenza virus type A. Fur-
ther, ganodermadiol is active against herpes simplex vi-
rus type 1, causing lip exanthema and other symptoms
(68). In vitro antiviral activity against influenza viruses
type A and B was demonstrated for mycelial extracts of
Kuehneromyces mutabilis (Schaeff.: Fr.) (69), two isolated
phenolic compounds from Inonotus hispidus (Bull.: Fr.) P.
Karst (70) and ergosterol peroxide, present in several
mushrooms (67,70–72).
Water-soluble lignins isolated from Inonotus obliquus
(Pers.: Fr.) inhibited HIV protease with an IC 50 value of
2.5 mg/mL (70). Anti-HIV activities were reported for
mycelial culture medium of L. edodes (LEM) and water-
-soluble lignin in LEM (71,72). Sulfated lentinan from L.
edodes completely prevented HIV-induced cytopathic ef-
fect (72). The protein-bound polysaccharides PSK and
PSP from Trametes versicolor (L.: Fr.) were also found to
have an antiviral effect on HIV and cytomegalovirus in
vitro (71). Besides immunostimulation, other effects of the
polysaccharide–protein complexes contribute to the anti-
viral activity, e.g. inhibition of binding of HIV-1 gp120 to
immobilized CD4 receptor and of reverse transcriptase
activity of viruses (72). Inhibition of HIV-1 reverse tran-
scriptase was caused by velutin, a ribosome inactivating
protein from Flammulina velutipes (M.A. Curtis: Fr.) P.
Karst (73). The maitake D-fraction (MD-fraction) from
Grifola frondosa (Dicks: F) S.F. Gray was tested in a long-
-term trial with 35 HIV patients. A total of 85 % of re-
sponders reported an increased sense of well-being with
regard to various symptoms and secondary diseases
caused by HIV. Twenty patients showed an increase in
CD4+ cell counts to 1.4–1.8 times and eight patients a
decrease to 0.8–0.5 times (74).
Cytostatic compounds
Many small molecular mass compounds exhibit cy-
totoxic activities against tumor cells. To them belong the
illudins, tricyclic sesquiterpenes from Omphalotus olea-
rius (DC.: Fr.) Singer and Lampteromyces japonicus (Ka-
wam.) Singer and their derivatives (75), the terpenoid
leaianafulvene (10) from Mycena leaiana (Berk.) Sacc.
(76), triterpenes (ganoderic acids Z, Y, X, W, V, T; lucial-
dehydes A, B, C and australic acid) from G. lucidum (77–
80) or Ganoderma australe (Fr.) Pat., acetoxyscirpenediol,
ergosterol peroxide (4) from P. tenuipes and sterols from
the mycelia of C. sinensis (Berk.) Sacc. (77–79). Acetoxy-
scirpenediol exerts its activity by inducing apoptosis in
leukemia cell lines in vitro (80). Apoptosis in HL-60 cells
could be induced by triterpenes from Ganoderma concin-
num Ryvarden (81). The triterpenes applanoxidic acids
A-H, isolated first from G. applanatum, were effective
against mouse skin tumor promoters, applanoxidic acid
B being the most potent of the acids. The activities were
shown in the short-term in vitro assay of Epstein–Barr
virus early antigen activation in Raji cells induced by
12-O-tetradecanoylphorbol-13-acetate (82,83). A deriva-
tive of illudin S has progressed to phase II in human
clinical trials (84). The specificity of the cytotoxic action
against tumor cells remains to be determined.
Phellinus linteus (Berk. & M. A. Curtis) Teng was
found to contain antiangiogenic activity in the chick em-
bryo chorioallantoic membrane assay (85) and to inacti-
vate cancer-related kinases (86). Antiangiogenic activity
was also reported for polysaccharides from A. brasiliensis
(87). The sesquiterpenoid cryptoporic acids A-G from
Cryptoporus volvatus (Peck) Murrill inhibit the tumor pro-
motion activity of okadaic acid in two-stage carcinoge-
nesis experiments. The effect is possibly related to their
strong radical scavenging activity (88). Antimutagenic
effects were found for methanolic extracts of P. ostreatus,
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Lactarius vellereus (Fr.) Fr., and for water extracts of A.
bisporus and G. lucidum. The genoprotective effect of A.
bisporus has been related to the enzyme tyrosinase (89–
91). A dried oyster mushroom (P. ostreatus) diet (5 %) re-
duced pathological changes in dimethylhydrazine-in-
duced colon cancer in rats but did not influence signifi-
cantly the incidence of tumors. This effect is explained
by the antioxidant properties of this mushroom and by
its fiber content (92).
Antiallergic compounds
Ethanolic extracts of the edible Japanese basidiomy-
cetes H. marmoreus, F. velutipes, Pholiota nameko (T. Ito) S.
Ito and Pleurotus eryngii (DC.: Fr.) Quél. show significant
antiallergic effects in mice (oxazolone-induced type IV
allergy) also after per os application (93). Some com-
pounds from G. lucidum (ganoderic acids C and D, cy-
clooctasulfur) inhibit the histamine release from rat mast
cells (94,95). Eating of Tricholoma populinum J. E. Lange
led to the regression of severe allergic symptoms in a
patient with thromboangitis obliterans and in another
patient with urticaria. The effects could be confirmed in
animal models, as one responsible compound ergosterol
peroxide was identified (96,97). Hispolon and hispidin,
isolated from fruit bodies of Indocalamus hispidus, inhibit
the chemiluminescence response of human mononuclear
blood cells and the mitogeninduced proliferation of spleen
lymphocytes of mice (98). There are many other com-
pounds or activities found in the mushroom, such as an-
tioxidative, hypoglycemic action, anti-inflammatory effect,
hepatoprotective compounds, psychoactive compounds
and activities (41).
Mushrooms and/or Mushroom Extracts
as Dietary Supplements
There is significant interest in the use of mushrooms
and/or mushroom extracts as dietary supplements based
on the facts that they have a lot of active compounds.
However, there are few experiments about epidemiolo-
gic and experimental studies that address the biological
activities of whole mushrooms or crude extracts by oral
administration to humans. There has only been one epi-
demiological study assessing the association between
mushroom intake and cancer, more specifically gastric
cancer (99). An inverse correlation between mushroom
intake and the risk of gastric cancer was found. Using
the risk of gastric cancer in relation to low mushroom
intake as the reference value, the probability ratio was
0.38 (95 % confidence interval, CI=0.21–0.66) for medi-
um intake and 0.30 (CI=0.15–0.62) for high intake.
An aqueous extract of Agaricus blazei Murill in the
drinking water given to rats and mice before chemical
cancer induction exhibited antimutagenic effects but was
ineffective when administered in the postinduction pe-
riod (100–102). Interestingly, the same strain of A. blazei
fed in dry powdered form to rats at 10 % of the diet ex-
hibited significant antimutagenic activity even when
given in the postinitiation period, suggesting that some
active constituent was lost during the aqueous extrac-
tion (103). Similar antimutagenic effects were reported
for diets containing powdered L. edodes (shiitake) (104,
105). These results suggest they could potentially pro-
vide additive, or even synergistic effects in the preven-
tion and treatment of cancer.
Oral administration of whole mushroom or extracts
to human cancer patients is the most important. A study
was conducted with orally administered polysaccharide
peptides (PSP) isolated from Coriolus versicolor in a total
of 68 patients with advanced (stages III or IV) non–small
cell lung cancer (106). The results show that leukocyte
and neutrophil counts rose significantly after PSP treat-
ment, whereas they decreased in the control group. Total
IgG and IgM levels were significantly increased in the
PSP group but not in the control group, with the differ-
ence between the groups being statistically significant. A
phase I/II study was conducted with GanoPoly, crude
polysaccharide fraction of G. lucidum (Curt.: Fr.) P. Karst,
600 mg given orally three times a day to patients with
advanced cancer (107). In a case series of eight patients
with various cancers (mostly stage III, 1 stage II, 1 stage
IV), who were given 100 mg of D-fraction, a polysaccha-
ride isolated from G. frondosa, daily for up to 34 months,
there was an, at times marked, increase in natural killer
cell activity (108). Based on a list of reduced or enhanced
parameters, the same group reported that a positive re-
sponse occurred in 23 of 36 cancer patients who took a
combination of MD-fraction (which appears to be identi-
cal to the D-fraction) and maitake (109).
As can be seen, only a few mushroom-derived sub-
stances are classified as drugs (lentinan, krestin and
schizoppyllan), the majority have been developed as di-
etary supplements. The principal mushroom products or
derivatives are in the form of powders, capsules or tab-
lets, made of dried fruiting bodies, extracts of fruiting
bodies or mixtures; or extract of mycelium with sub-
strate, biomass or extract from liquid fermentation (110).
The US dietary supplement sales were estimated to be
US$14.0 billion in 2000 (111). It is believed that the mush-
room dietary supplements will be recognized and mar-
keted extensively.
Conclusion
There has been a lot of progress in mushroom sci-
ence and biotechnology in the last decade. The optimiza-
tion of PFGE separation of fungal chromosomes allowed
the study of the molecular karyotype of mushrooms and
the assignment of genes to chromosomes, such as with
13 chromosomes of A. bisporus (31 Mbp) and 11 pairs of
chromosomes of P. ostreatus. According to the GenBank,
there are 115 genes encoded from Coprinus cinereus, 87
genes in Schizophyllum, 46 in Pleurotus, 25 genes encoded
in Agrocybe and Lentinula, 23 genes encoded in Agaricus
bisporus, 12 genes in Genoderma, 7 in Flammulina, 6 in Po-
lyporus and Pholiota, 3 in Hericium and Grifora. There are
2 genes encoded in Volvariella volcacea, and 1 in Auricula-
ria polytricha.
Cross breeding continues to be the principal me-
thod, but it is accompanied by analyses of RAPD or
RFLPs methods. The use of genetic makers is straight-
forward for monogenic traits that segregate in distinct
phenotypes, such as cap colour. These markers have
been used to introduce the brown cap colour of a wild
line into a commercial large hybrid via introgression
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breeding. Another example is the introduction of spo-
reless trait to the commercial strain of Pleurotus ostreatus.
The complex traits such as yield, resistance to disease
and quality characteristics, more than one quantitative
trait locus (QTL) have been found and used in practice.
The transformants or transgenic mutant strains were ob-
tained by Agrobacterium system or particle bombard-
ment.
Pharmaceutically active mushroom compounds con-
tinue to be the main subject of most researches, includ-
ing isolation, chemical structures and experiments in vitro
or in vivo. At least 651 species representing 182 genera
of hetero- and homobasidiomycetes mushrooms contain
antitumor or immunostimulating polysaccharides. The
lipid fraction was found to contain a compound with
antitumor activity, subsequently identified as ergosterol.
The lipid fraction exhibited antioxidant activity and in-
hibited the cyclooxygenase enzymes. Ergosterol was again
identified as one of the most active constituents. Its inhi-
bition can result in the inhibition of tumor development,
and it appears to be beneficial even in some established
tumors. Other mushroom constituents may inhibit pro-
motion or progression by exerting direct cytotoxicity
against tumor cells, interfering with tumor angiogenesis,
or upregulating other nonimmune tumor-suppressive
mechanisms.
New sesquiterpenoid hydroquinones inhibit the
growth of methicillin-resistant bacteria. Steroids and ox-
alic acid are agents responsible for the antimicrobial ef-
fect. Several triterpenes, water-soluble lignins, sulfated
polysaccharides and protein-bound polysaccharides are
active as antiviral agents against human immunodefi-
ciency virus type 1 (HIV-1).
Many small molecular mass compounds exhibit cy-
totoxic activities against tumor cells, such as illudins,
leaianafulvene, triterpenes (ganoderic acids), acetoxy-
scirpenediol, ergosterol peroxide or sterols. The sesqui-
terpenoid cryptoporic acids A-G inhibit the tumor pro-
motion activity. Ethanolic extracts show significant anti-
allergic effects. There are many other compounds or ac-
tivities found in the mushrooms, such as antioxidative,
hypoglycemic action, anti-inflammatory effect, hepatopro-
tective compounds, psychoactive compounds and activi-
ties.
However, only a few mushroom-derived substances
are classified as drugs (lentinan, krestin and schizophyl-
lan), the majority have been developed as dietary supple-
ments. The principal mushroom products or derivatives
are in the form of powders, capsules or tablets made of
dried fruiting bodies, extracts of fruiting bodies or mix-
tures; or extract of mycelium with substrate, biomass or
extract from liquid fermentation. The diet supplement
sales were estimated to be US$14.0 billion in 2000. It is
believed that the mushroom diet supplements will be
recognized and marketed extensively in the next decade.
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